VistaGen Therapeutics, Inc. (VTGN) Reports Q1 Loss, Misses Revenue Estimates

VistaGen Therapeutics, Inc. (VTGN) came out with a quarterly loss of $0.47 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.35 per share a year ago. These figures are adjusted for non-recurring items. A quarter ago, it was expected that this company would post a loss of $0.52 per share when it actually produced a loss of $0.43, delivering a surprise of +17.31%.Over the last four quarters, the company has surpassed consensus EPS estimates two times.VistaGen Therapeutics, whi ...